Orphazyme A/S (NASDAQ:ORPH) traded at a new 52-week low today of $7.53. Approximately 121,000 shares have changed hands today, as compared to an average 30-day volume of 6,000 shares.
Orphazyme A/S is a Danish biotech company. It is engaged in the development of paradigm-changing medicines for the treatment of protein misfolding diseases. The company’s lead candidate, arimoclomol, is in development for four severe orphan diseases; two neuromuscular diseases, sporadic Inclusion Body Myositis and Amyotrophic Lateral Sclerosis, and two lysosomal storage diseases, Niemann-Pick disease Type C and Gaucher disease.
Over the past year, Orphazyme A/S has traded in a range of $7.53 to $14.78 and is now at $8.60.
Orphazyme A/S (NASDAQ:ORPH) has potential upside of 49.0% based on a current price of $8.60 and analysts’ consensus price target of $12.81.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer